In Regulatory First, Myeloma Drug Approved Based on MRD Negativity.

FDA approves iberdomide for multiple myeloma based on minimal residual disease negativity, marking the first such approval for the disease.

• Why it matters: This approval highlights a shift toward using minimal residual disease status as a key endpoint, which could accelerate drug development and personalized treatment strategies in multiple myeloma.
• What they did: The study involved evaluating iberdomide's efficacy through MRD negativity, supported by the development of a new class of targeted protein degraders, with several more in clinical trials.
• The result: This approval enables more precise treatment monitoring and paves the way for innovative therapies, potentially improving outcomes for patients with multiple myeloma.